Clinical Trials in Dementia
Dementia, particularly Alzheimer's disease (AD), is increasing by patient population included in clinical trials. The methodology for trials of AD patients have been defined in terms of outcomes, standard measures and analytic techniques. Trial methodology is evolving with experience as new potential therapies become available. Screening criteria, instrumentation choices, duration of trials and analytic strategies may have a profound impact on the conclusions that can be derived from trials. The components of AD trials are reviewed in detail in this chapter.
c1 Correspondence should be addressed to: Jeffrey L. Cummings, MD, Departments of Neurology and Psychiatry and Biobehavioral Sciences, Reed Neurological Research Center, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Suite 2-238, P.O. Box No. 951769, Los Angeles, CA 90095-1769, USA; Tel: 310 206 5239; Fax: 310 206 5287; Email: email@example.com